Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme
Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces positive top-line results from the RED DESERT study with repeated dose alfapump DSR® (Direct Sodium Removal) therapy in diuretic-resistant heart failure patients.
SAHARA DESERT, the study of the alfapump DSR in diuretic-resistant heart failure patients with residual congestion is on track to start before the end of this quarter, with interim results expected before year-end and top-line results expected in H2 2022.
In addition, Sequana Medical announces that it will expand its DSR development program with the addition of short-term DSR therapy. Short-term DSR is expected to achieve faster adoption of DSR therapy by the clinical community, support alfapump DSR market entry, expand the potential market opportunity and target earlier entry into the U.S. market. MOJAVE DESERT, the first U.S. feasibility study of short-term DSR therapy, is planned to start in H2 2022. Based on FDA feedback, SONORAN DESERT, the U.S. efficacy study of alfapump DSR therapy, is now planned to commence in mid-2023 to allow completion of long-term pre-clinical studies.
Fluid and sodium overload is an important clinical problem in renal disease / hemodialysis and Sequana Medical is evaluating the opportunity for DSR therapy to improve clinical outcomes and is supporting the clinical work of Dr. McIntyre of Lawson Health Research Institute, Ontario, Canada.
Ian Crosbie, Chief Executive Officer at Sequana Medical, commented: “These RED DESERT results are very exciting and further confirm the potential clinical benefits of our alfapump DSR therapy. Repeated alfapump DSR therapy not only managed the fluid and sodium balance throughout the study without the need of any loop diuretics but crucially it also restored patients’ diuretic response and overall cardio-renal status. We are very encouraged by the durability of the reduction in loop diuretics and believe our novel alfapump DSR therapy has the potential to transform the treatment of this large and growing patient group.
In light of the success of RED DESERT, we have concluded the study at eight patients so that we can move on to the SAHARA DESERT study as soon as possible, where we will be treating our anticipated patient population.
We are expanding our DSR development programme into short-term DSR treatment, complementing our long-term alfapump DSR treatment. We believe that short-term DSR therapy plays a crucial role in establishing this breakthrough treatment and enhances the market opportunity for alfapump DSR therapy. This combined strategy of short-term and long-term DSR therapy will reinforce our leadership role in addressing diuretic-resistant fluid overload.
Strong top-line results from RED DESERT
Eight patients diagnosed with stable chronic heart failure on high dose oral diuretics (mean furosemide equivalent dose of 323 mg/day) were implanted with the alfapump DSR system and underwent up to six weeks of DSR therapy whilst their loop diuretic treatment was withheld. The heart failure patients enrolled in the study had an overall high disease severity at baseline, including a mean left ventricular ejection fraction of 24% and mean NT-proBNP of 4,589 pg/mL.
During the course of the six-week therapy, none of the patients required any loop diuretics, demonstrating the ability of repeated alfapump DSR therapy to effectively manage their fluid and sodium balance. After the six-week study, the mean response to a standard diuretic challenge (40 mg intravenous furosemide) improved by more than 250% (p<0.001 vs baseline, N=7) as measured by the six-hour excretion of sodium. This improvement of diuretic efficiency was maintained with a 79% reduction of average loop diuretic dose at a median of 10 months post-study versus baseline and all patients were receiving less than or equal to 50% of their baseline diuretic dose (maximum follow-up post-study is 12.5 months).
The results clearly show a significant benefit to the cardio-renal function of these patients with a mean 30% reduction in NT-proBNP (p<0.001 vs baseline, N=7), mean 22% improvement in estimated glomerular filtration rate (p<0.001 vs baseline, N=7) and mean 22% reduction in creatinine (p<0.001 vs baseline, N=7). Typically, managing the fluid balance in these patients through aggressive diuretic use would be associated with declining cardio-renal function, whilst RED DESERT showed that both of these functions were improved following repeated alfapump DSR therapy.
In all patients, there were no clinically relevant changes in serum sodium levels or progressive hyponatremia. There were two serious adverse events in two of the last three patients, both having advanced heart failure. There was one transient ischemic attack (fully recovered) and one sudden cardiac death. The Data Monitoring Committee (DMC) assessed both events as possibly related to the study therapy or procedure but unlikely to be related to the device. The site Principal Investigator assessed that neither event was related to the study therapy, procedure or device.
Dr. Jozef Bartunek, Interventional Cardiologist at Onze-Lieve-Vrouw Hospital in Aalst (Belgium) and Principal Investigator of the RED DESERT study, commented: “These results confirm that alfapump DSR therapy is well tolerated and manages to quickly maintain a neutral sodium balance and stable body weight over six weeks, despite complete withdrawal of loop diuretics. The substantial improvement in diuretic response together with the meaningful improvement in NT-proBNP and renal function could be a potential game-changer.”
Dr. Jeffrey Testani, Associate Professor at Yale University and Heart Failure Scientific Advisor of Sequana Medical, added: “There is a significant need for novel therapies for sodium and fluid removal in heart failure, given the toxicity of loop diuretics and the high prevalence of resistance to these agents. The simultaneous normalisation of diuretic response and improvement in cardio-renal status of the RED DESERT patients is a never before seen treatment effect and could translate into important long-term clinical benefits in heart failure patients. I am looking forward to further clinical research to better understand the cardio-renal benefits of alfapump DSR therapy and its application to heart failure patients in urgent need of improved treatment options.”
SAHARA DESERT on track to start before end Q2 2021 – Interim results end 2021, Top-line results H2 2022
The SAHARA DESERT study will build on the learnings from RED DESERT and moves into sicker heart failure patients - those with residual congestion and for whom oral diuretics are no longer effective at preventing fluid overload. The study in 20 patients will evaluate the treatment algorithm and the ability of alfapump DSR therapy to eliminate the residual congestion and restore the correct fluid status (euvolemia) for up to 22 weeks. Interim results are expected before end 2021 with top-line results planned for H2 2022.
Expanding DSR development programme with short-term as well as long-term DSR therapy
As a result of the positive results from RED DESERT, the DSR development programme is being expanded into short-term DSR therapy to complement long-term alfapump DSR therapy. The intention is to enable faster adoption of DSR therapy by the clinical community by reducing barriers to adoption, support alfapump DSR market entry, expand the potential market opportunity and target earlier entry into the U.S. market.
A key element of the DSR programme is the development of DSR Infusate 2.0, Sequana Medical’s proprietary DSR Infusate. The intention is to deliver an infusate with a superior therapeutic profile as well as a high margin recurring revenue flow to accompany alfapump sales. Pre-clinical development work on DSR Infusate 2.0 is ongoing and preparations are being made for Chemistry, Manufacturing and Controls (CMC) activities.
Short-term DSR therapy will involve repeated DSR treatment for approximately 2 weeks, using DSR Infusate 2.0 in combination with a peritoneal catheter (instead of the alfapump). MOJAVE DESERT, the U.S. proof-of-concept study of short-term DSR therapy is scheduled to start in H2 2022. The study design will leverage the learnings from SAHARA DESERT as well as the anticipated superior therapeutic profile of DSR Infusate 2.0. The use of short-term DSR therapy without the alfapump has been enabled by the fundamental DSR patents that have been granted in the U.S. and Europe, and are under review elsewhere in the world.
Following discussions with the FDA, SONORAN DESERT, the U.S. controlled efficacy study of alfapump DSR is now planned to commence in mid-2023 to enable completion of long-term pre-clinical studies prior to study commencement.
Evaluating opportunity for DSR therapy in fluid and sodium overload in renal disease / hemodialysis
The effective management of fluid and sodium overload is a significant problem in renal disease / hemodialysis. Sequana Medical is evaluating the opportunity for DSR therapy to address this poorly met clinical need and is supporting the work of Dr. Chris McIntyre of the Lawson Health Research Institute, Ontario, Canada who is evaluating the use of DSR therapy in effective volume management and sodium removal in prevalent hemodialysis patients (ClinicalTrials.gov NCT04603014). Results of this work will be shared in due course.